• Wondering if Cardinal Health at US$195.24 is still offering value after a strong multi year run? This article breaks down what the current price might be saying about the stock.
• The share price has eased recently, with a 2.3% decline over 7 days, a 7.9% decline over 30 days and a 5.1% decline year to date, even though the 1 year return stands at 32.0% and the 5 year return is 276.7%.
• Recent coverage around Cardinal Health has focused on its position in healthcare distribution and ongoing sector wide interest in cost efficiency and supply chain reliability. This backdrop helps frame why the stock has delivered very large 3 year returns of 146.6%, while still seeing short term pullbacks.
• Cardinal Health currently holds a 3/6 valuation score. Next up is a look at how that score is built using different valuation methods and why some investors prefer an even more holistic way of thinking about value at the end of this article.

Approach 1: Cardinal Health Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a business might be worth by projecting future cash flows and discounting them back to today, so you can compare that value with the current share price.

For Cardinal Health, the model used is a 2 Stage Free Cash Flow to Equity approach based on cash flow projections. The latest twelve month free cash flow is about $4.40b. Analyst inputs are used for the first part of the forecast period, with free cash flow projections such as $2.98b in 2026 and $3.35b in 2027. Simply Wall St then extrapolates beyond the explicit analyst horizon, reaching a projected $4.28b in 2030.

When all these projected cash flows are discounted back, the model suggests an estimated intrinsic value of about $468.78 per share. Against a share price of around $195.24, this implies the stock is 58.4% undervalued on this DCF view.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Cardinal Health is undervalued by 58.4%. Track this in your watchlist or portfolio, or discover 51 more high quality undervalued stocks.

Approach 2: Cardinal Health Price vs Earnings

For a profitable company, the P/E ratio is a familiar way to think about value because it links what you pay directly to the earnings the business is generating today. A higher P/E can reflect stronger growth expectations or lower perceived risk, while a lower P/E can point to more modest growth assumptions or higher risk.

Cardinal Health currently trades on a P/E of 29.55x, compared with a Healthcare industry average of about 24.86x and a peer average of 24.03x. On these simple comparisons, the shares are priced above both the wider industry and peer group.

Simply Wall St also calculates a "Fair Ratio" of 27.12x. This is the P/E level it would expect for Cardinal Health given factors such as earnings growth, profit margins, industry, market cap and company specific risks. This tailored yardstick can be more informative than a basic comparison with peers or the sector because it adjusts for the company’s own characteristics rather than assuming all businesses deserve similar multiples. Since the current P/E of 29.55x sits above the Fair Ratio of 27.12x, the shares screen as overvalued on this metric.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies.

Upgrade Your Decision Making: Choose your Cardinal Health Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so Narratives are worth knowing because they let you attach a clear story about Cardinal Health to the numbers you care about, such as your own fair value, revenue, earnings and margin expectations. You can then link that story to a forecast and a price target that you can compare with the current share price to help decide whether the stock looks attractive or expensive.

On Simply Wall St's Community page, Narratives are easy to use and update automatically when new information like earnings, news or analyst targets arrives. This allows you to see in real time how your view compares with others and how that affects estimated fair value versus price.

For Cardinal Health, one investor might build a Narrative close to the bullish end of analyst expectations, using a fair value around US$275.00 that is based on assumptions such as revenue of US$317.9b, earnings of US$2.6b and a P/E of 26.3x by 2029. Another investor might align more with the cautious US$200.00 view, stressing risks around regulation, competition, reimbursement and tariffs. Narratives allow both perspectives to be tracked side by side so you can judge which story you find more reasonable.

Do you think there's more to the story for Cardinal Health? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.